Market capitalization | $3.44m |
Enterprise Value | $-6.76m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.67 |
P/B ratio (TTM) P/B ratio | 0.19 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-11.38m |
Free Cash Flow (TTM) Free Cash Flow | $-10.14m |
Cash position | $10.64m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:
1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -11 -11 |
29%
29%
|
EBIT (Operating Income) EBIT | -11 -11 |
29%
29%
|
Net Profit | -24 -24 |
340%
340%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MyMD Pharmaceuticals, Inc. is a clinical stage pharmaceutical company which engages in extending healthy lifespan. It involves in developing and commercializing therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. The company is headquartered in Baltimore, MD.
Head office | United States |
CEO | Christopher Chapman |
Employees | 6 |
Founded | 1989 |
Website | tnfpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.